Severe PTSD characterized by lower oxytocin and higher vasopressin levels

Research finds PTSD marked by reduced oxytocin and elevated vasopressin, suggesting AVP/OT ratios as potential biomarkers for diagnosis and treatment response.

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 18, 2024

DoxyPEP reduces chlamydia and syphilis rates in routine care

A new study has found that rates of chlamydia and syphilis plummet among people prescribed doxycycline for sexually transmitted infection prevention in routine clinical care.

January 6, 2025

Inhibrx’s early colorectal cancer data clouded by patient death

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 23, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.